Experimental drug aims to shield dialysis Patients' brains

NCT ID NCT07234890

Recruiting now Disease control Sponsor: London Health Sciences Centre Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an experimental drug called AV-001 can protect the brain from injury caused by hemodialysis. The drug is designed to strengthen blood vessels in the brain and reduce inflammation. Researchers will enroll 60 adults who have been on dialysis for at least three months and use MRI scans and blood tests to measure effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AV-001 (an experimental drug given by IV injection)
What this could lead to: If it works, this could point toward a way to protect the brains of people on dialysis, potentially reducing cognitive decline and stroke risk.
What could go wrong: This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The drug is experimental and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE REQUIRING HEMODIALYSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMODIALYSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

London Health Sciences Centre
RECRUITING

London, Ontario, N6A 5W9, Canada

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.